# A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

> **NCT07518043** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 174 (estimated)

## Conditions studied

- Esophageal and/or Cardia Cancer
- Melanoma
- Urothelial Carcinoma (UC)

## Interventions

- **DRUG:** HLX18
- **DRUG:** OPDIVO®

## Key facts

- **NCT ID:** NCT07518043
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-08-12
- **Final completion:** 2028-06-13
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07518043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07518043, "A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07518043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*